Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Sun Finally Gains Control Of Taro As Founders Relent; Charts Out Aggressive Investment And Growth Plans

This article was originally published in PharmAsia News

Executive Summary

HYDERABAD - Bound by Israel's Supreme Court verdict earlier this month, drug firm Taro's founders - the Levitt and Moros families - have finally conceded management control of the 60-year old company that specializes in dermatology products to Sun Pharma - India's largest company by market capitalization

You may also be interested in...

A Deal A Month? After Dusa, India’s Sun Bags URL’s Generics Business As Takeda Keeps Colcrys

Sun Pharma continues its acquisition spree in the U.S. under new Chairman Israel Makov.

Will India’s Sun Rise On Stada? Bankers, Analysts Divided On Risks, Benefits

Stada’s financial woes may not be primary factors for Sun to bid but analysts reason there may be value accretive points.

Inside India’s Most Valued Pharma Company: Sun Pharma Chief Dilip Shanghvi Lays Out Future Growth Plans

Sun Pharma chief will look for opportunities in emerging markets, but buyouts will not be large.

Related Content




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts